Guzel Faritovna Proklova

Guzel Faritovna Proklova

Auto-generated profile, based on publicly available information

Guzel Faritovna Proklova

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Russian Journal of Woman and Child Health
Verified
Journal Article
Open access
RCR.A. Chilova
R.A. Chilova
GPG.F. Proklova
G.F. Proklova
NGN.V. Goncharenko
N.V. Goncharenko
Диагностика и лечение бактериального вагиноза. Правильный выбор препаратов, обладающих наибольшей эффективностью воздействия на большинство микроорганизмов, вызывающих бактериальный вагиноз. Клиндамицин

17 March 2026 in V.F.Snegirev Archives of Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
YLYuliya V. Luzik
Yuliya V. Luzik
SSSvidinskaya Svidinskaya
Svidinskaya Svidinskaya
DBDmitrii V. Baburin
Dmitrii V. Baburin
MAMikhail B. Ageev
Mikhail B. Ageev
GPGuzel F. Proklova
Guzel F. Proklova
ESElena A. Sosnova
Elena A. Sosnova
Currently, the problem of overweight and obesity has acquired global significance due to the high prevalence of these conditions and the associated multisystem pathological conditions, including reproductive disorders in both men and women. Contemporary medicine strongly recommends weight reduction to prevent metabolic complications and obesity-related comorbidities. The most effective and fundamental approach remains lifestyle modification, including a hypocaloric diet and moderate physical activity. However, a proportion of patients demonstrate resistance to such changes, necessitating the use of pharmacological agents and, in some cases, surgical treatment. Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated high efficacy in reducing body weight and improving glycemic control in patients with obesity and type 2 diabetes mellitus. However, data on the effects of semaglutide on the female reproductive system remain limited, as long-term clinical observations and studies under extreme conditions have been predominantly conducted in animal models. Particular attention is given to the effects of the drug in women of reproductive age, including its impact during preconception, the first trimester of pregnancy, and lactation, when both inadvertent and intentional exposure may have unpredictable consequences for the fetus and infant. This study presents a systematic review of current evidence regarding the use of semaglutide in female patients with obesity and examines the associated risks and contraindications during specific physiological states such as pregnancy and lactation. The findings are of substantial importance for developong clinical guidelines and establishing safe therapeutic strategies, which are essential for preserving reproductive health and supporting demographic stability.


10 December 2025 in V.F.Snegirev Archives of Obstetrics and Gynecology
Verified
Journal Article
Closed access
PDF file
MSMaria Aleksandrovna Sukhanova
Maria Aleksandrovna Sukhanova
AKAnastasia O. Kiryanova
Anastasia O. Kiryanova
MAMikhail B. Ageev
Mikhail B. Ageev
SSSvidinskaya Svidinskaya
Svidinskaya Svidinskaya
NZNatalia S. Zemlina
Natalia S. Zemlina
КОКирьянова Анастасия Олеговна
Кирьянова Анастасия Олеговна
This systematic review aims to summarize current evidence on vitamin deficiencies in pregnant women, their clinical consequences, and approaches to nutritional status correction during gestation. Given the increasing prevalence of hypovitaminosis among pregnant women, particularly deficiencies of folic acid, vitamin D, and vitamin B12, the clinical importance of early diagnosis and individualized therapy is growing. The article analyzes studies published over the past 5 years by Russian and international authors, including randomized controlled trials, meta-analyses, cohort studies, and international clinical guidelines. Key micronutrients, their effects on the course of pregnancy, maternal and fetal outcomes, and factors contributing to impaired vitamin metabolism, including genetic polymorphisms (MTHFR, VDR, TCN2), were evaluated. The review presents approaches to laboratory diagnosis of vitamin deficiencies, principles of rational dietary therapy, and the use of vitamin–mineral supplements, as well as the potential of personalized nutritional correction. The need for incorporating vitamin status assessment into preconception care and antenatal management algorithms for women at risk is substantiated. The findings of this review emphasize the role of nutritional support as an essential component in the prevention of obstetric and perinatal conditions.

20 May 2026 in V.F.Snegirev Archives of Obstetrics and Gynecology
Verified
Journal Article
Closed access
OGOksana Yu. Gorbenko
Oksana Yu. Gorbenko
SSSvidinskaya Svidinskaya
Svidinskaya Svidinskaya
MBMariia A Bagrintseva
Mariia A Bagrintseva
ABAisha Bozheva
Aisha Bozheva
NMNaira Martirosyan
Naira Martirosyan
ESElena A. Sosnova
Elena A. Sosnova
MicroRNAs (miRNAs) are one of the most actively studied classes of small non-coding RNAs in modern medicine. A review of current studies on this topic is presented both in Russian and in English. The key advantage of microRNAs as potential biomarkers is their high stability in biological fluids (blood, urine, amniotic fluid, cervical mucus), tissue specificity and the possibility of non-invasive determination. In recent years, various studies have been conducted to identify such a biomarker as microRNAs in the blood plasma of women diagnosed with endometriosis. Complex intracellular interactions between signaling pathways suggest that microRNAs may be related to the pathophysiology of endometriosis, as they regulate numerous processes, including apoptosis and cell proliferation. The analyzed studies demonstrate that changes in the expression of microRNAs are associated with a number of pregnancy complications, such as disorders of uteroplacental-fetal blood flow, preeclampsia. Modern data allow us to consider microRNA dysregulation as one of the central molecular mechanisms for the development of isthmic-cervical insufficiency, and the results of pilot studies confirm the prospects for the use of mRNA technologies for the pathogenetic correction of chronic placental insufficiency. Promising areas for future research are large-scale validation of miRNA biomarkers, the development of safe methods for their local modulation, and an in-depth study of the role of exosomes in the pathogenesis of many diseases.

31 March 2026 in V.F.Snegirev Archives of Obstetrics and Gynecology
Verified
Journal Article
Closed access
PDF file
OFOlga V. Filimonova
Olga V. Filimonova
SPShati K. Pandya
Shati K. Pandya
VOVasilii B. Osadchev
Vasilii B. Osadchev
GPGuzel Faritovna Proklova
Guzel Faritovna Proklova
OPOlesya S. Pobedinskaya
Olesya S. Pobedinskaya
ПСПобединская Олеся Сергеевна
Побединская Олеся Сергеевна
According to the World Health Organization, infertility affects 17.5% of the adult population worldwide and remains a serious medical and social challenge. Despite significant progress in assisted reproductive technologies, the treatment of infertility associated with endometrial disorder and ovarian dysfunction remains relevant and requires the search for new therapeutic approaches. This review analyzes current data from Russian and international sources published over the past 5 years on the use of autologous platelet-rich plasma (PRP) as a promising therapeutic modality in assisted reproductive technology programs. The search for published data was conducted in PubMed, eLibrary, and Google Scholar databases. Analysis of the publications demonstrated that PRP therapy is clinically effective in treating thin endometrium, recurrent implantation failure, and premature ovarian insufficiency and may also improve the clinical pregnancy rate. However, the available studies are limited by small sample sizes and nonrandomized designs, precluding definitive conclusions regarding the efficacy and safety of PRP therapy. Additionally, different routes of administration, injected plasma volumes, and platelet concentrations are currently in use. However, their efficacy has not been compared against one another but only against control groups receiving conservative therapy. This technology requires further investigation in randomized clinical trials to develop standardized protocols and evaluate long-term outcomes.